Drug intelligence / Profile preview

RO4929097 + bevacizumab

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of RO4929097, a gamma-secretase inhibitor targeting the Notch signaling pathway, and bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). This combination was investigated primarily for the treatment of recurrent malignant glioma. The scientific rationale for combining these agents stems from the understanding that Notch signaling promotes tumor invasion and tumor-related angiogenesis, while bevacizumab blocks tumor growth by inhibiting angiogenesis.

Targets

VEGFA (Vascular endothelial growth factor A)GSEC (Gamma-Secretase Complex)

Beyond the preview

Go deeper on RO4929097 + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO4929097 + bevacizumab.

Explore the full profile